PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022

News provided by

Dec 19, 2013, 03:38 ET

LONDON, Dec. 19, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022". Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will shift due to changes being made to the UK MenC schedule (DOH, 2013b). Meningitec will lose sales due to its elimination from the single primary dose, with patient share expected to be made up by Menjugate and NeisVac-C.

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK
Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 15
3.2 Symptoms 17
3.3 Prognosis 18
4 Disease Management 19
4.1 Meningococcal Immunization Policy 20
4.2 United Kingdom 22
4.2.1 Meningococcal Immunization Recommendations and Policies 22
4.2.2 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 26
5.3 Product Profiles – Major Brands 28
5.3.1 Menveo 28
5.3.2 Nimenrix 31
5.3.3 Menitorix 34
5.3.4 Meningitec 37
5.3.5 Menjugate 40
5.3.6 NeisVac-C 42
5.3.7 Menomune 45
5.3.8 Bexsero 48
6 Opportunity and Unmet Need 51
6.1 Overview 51
6.2 Unmet Needs 52
6.2.1 Unmet Need: Protection Against Serogroup B Disease 52
6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine 53
6.2.3 Unmet Need: More Cost-Effective Vaccines 54
6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents 55
6.2.5 Unmet Need: Immunogenic Infant Vaccines 56
6.2.6 Unmet Need: Improved Vaccination Coverage Rates 57
6.2.7 Unmet Need: Increased Patient Awareness and Education 58
6.3 Unmet Needs Gap Analysis 59
6.4 Opportunities 59
6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations 59
6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants 60
6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets 61
7 Pipeline Assessment 62
7.1 Overview 62
7.2 Promising Vaccines in Clinical Development 63
7.2.1 MnB rLP2086 65
7.3 Promising Vaccines in Early Clinical Development 70
8 Market Outlook 71
8.1 United Kingdom 71
8.1.1 Forecast 71
8.1.2 Key Events 73
8.1.3 Drivers and Barriers 75
9 Appendix 77
9.1 Bibliography 77
9.2 Abbreviations 83
9.3 Methodology 85
9.4 Forecasting Methodology 85
9.4.1 Vaccine Coverage 86
9.4.2 Vaccine Approval vs. Routine Schedule Inclusion 86
9.4.3 Vaccines Included 87
9.4.4 Key Launch Dates 88
9.4.5 General Pricing Assumptions 89
9.4.6 Individual Vaccine Assumptions 89
9.4.7 Pricing of Pipeline agents 94
9.5 Physicians and Specialists Included in this Study 95
9.6 About the Authors 99
9.6.1 Authors 99
9.6.2 Reviewers 99
9.6.3 Global Head of Healthcare 100
9.7 About GlobalData 101
9.8 Disclaimer 101

List of Tables

Table 1: Symptoms of Meningococcal Disease 17
Table 2: Meningococcal Immunization Recommendation Agencies by Country 20
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 21
Table 4: Leading Vaccines for Meningococcal Disease, 2012 27
Table 5: Product Profile – Menveo 29
Table 6: Menveo SWOT Analysis, 2012 31
Table 7: Product Profile – Nimenrix 32
Table 8: Nimenrix SWOT Analysis, 2012 34
Table 9: Product Profile – Menitorix 35
Table 10: Menitorix SWOT Analysis, 2012 37
Table 11: Product Profile – Meningitec 38
Table 12: Meningitec SWOT Analysis, 2012 39
Table 13: Product Profile – Menjugate 41
Table 14: Menjugate SWOT Analysis, 2012 42
Table 15: Product Profile – NeisVac-C 43
Table 16: NeisVac-C SWOT Analysis, 2012 44
Table 17: Product Profile – Menomune 46
Table 18: Menomune SWOT Analysis, 2012 47
Table 19: Product Profile – Bexsero 49
Table 20: Bexsero SWOT Analysis, 2012 50
Table 21: Overall Unmet Needs – Current Level of Attainment 51
Table 22: Clinical Unmet Needs – Gap Analysis, 2012 59
Table 23: Meningococcal Vaccines – Phase Pipeline, 2012 64
Table 24: Comparison of Vaccines in Development for Meningococcal Disease, 2012 65
Table 25: Product Profile – MnB rLP2086 66
Table 26: MnB rLP2086 SWOT Analysis, 2012 69
Table 27: Sales Forecasts ($m) for Meningococcal Vaccines in the United Kingdom, 2012–2022 72
Table 28: Key Events Impacting Sales for Meningococcal Vaccines in UK, 2012–2022 74
Table 29: United Kingdom Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022 75
Table 30: Key Launch Dates 88
Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 98

List of Figures

Figure 1: Membrane Structure of N. meningitidis 14
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012–2022 64
Figure 3: Sales for Meningococcal Vaccines in the United Kingdom by Vaccine Class, 2012–2022 73

Read the full report:
PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022
http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_meningococcal_vaccines_uk_drug_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication